MATN3 and bladder transitional cell carcinoma: As presented in Fig 3A, the results demonstrated that higher expression of MATN3 was significantly associated with shorter survival in patients with BLCA, CESC, HNSC, LGG, LIHC, MESO, OV, PCPG, and STAD.